{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:06:58Z","timestamp":1791112018125,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is an incurable adult leukemia characterized by disrupted apoptosis. OSU03012 is a bioavailable third-generation celecoxib derivative devoid of cyclooxygenase-2 inhibitory activity that potently induces apoptosis in prostate cancer cell lines and is being developed as an anticancer therapy in the National Cancer Institute (NCI) Rapid Access to Intervention Development (RAID) program. We assessed the ability of OSU03012 to induce apoptosis in primary CLL cells and the mechanism by which this occurs. The LC50 (lethal concentration 50%) of OSU03012 at 24 hours was 7.1 \u03bcM, and this decreased to 5.5 \u03bcM at 72 hours. Additionally, we have demonstrated that OSU03012 mediates apoptosis by activation of the intrinsic, mitochondrial pathway of apoptosis but also activates alternative cell death pathways that are caspase independent. The early activation of both caspase-dependent and -independent pathways of apoptosis is novel to OSU03012 and suggests it has great potential promise for the treatment of CLL. Moreover, unlike the great majority of therapeutic agents used to treat leukemia or other forms of cancer, OSU03012 induces cell death entirely independent of bcl-2 expression. Overall, these data provide justification for further preclinical development of OSU03012 as a potential therapeutic agent for CLL.<\/jats:p>","DOI":"10.1182\/blood-2004-05-1957","type":"journal-article","created":{"date-parts":[[2004,9,29]],"date-time":"2004-09-29T01:28:26Z","timestamp":1096421306000},"page":"2504-2509","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2\u2013independent mechanism"],"prefix":"10.1182","volume":"105","author":[{"given":"Amy J.","family":"Johnson","sequence":"first","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuxiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Jefferson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mone","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grever","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Shih","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus; the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus; and the Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223455579200_REF1","doi-asserted-by":"crossref","unstructured":"Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin.2002;52: 23-47.","DOI":"10.3322\/canjclin.52.1.23"},{"key":"2020021223455579200_REF2","doi-asserted-by":"crossref","unstructured":"Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol.2000;12: 22-29.","DOI":"10.1097\/00001622-200001000-00004"},{"key":"2020021223455579200_REF3","doi-asserted-by":"crossref","unstructured":"Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96: 2655-2663.","DOI":"10.1182\/blood.V96.8.2655"},{"key":"2020021223455579200_REF4","doi-asserted-by":"crossref","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med.2000;343: 1750-1757.","DOI":"10.1056\/NEJM200012143432402"},{"key":"2020021223455579200_","doi-asserted-by":"crossref","unstructured":"Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98: 2319-2325.","DOI":"10.1182\/blood.V98.8.2319"},{"key":"2020021223455579200_REF6","unstructured":"Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347: 1432-1438."},{"key":"2020021223455579200_REF7","doi-asserted-by":"crossref","unstructured":"Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an up-dated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105: 49-53.","DOI":"10.1182\/blood-2004-03-0796"},{"key":"2020021223455579200_REF8","unstructured":"Wierda W, O'Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia [abstract]. Blood. 2001;98: 3210a."},{"key":"2020021223455579200_REF9","doi-asserted-by":"crossref","unstructured":"Hsu AL, Ching TT, Sen G, et al. Novel function of phosphoinositide 3-kinase in T cell Ca2+ signaling. A phosphatidylinositol 3,4,5-trisphosphate-mediated Ca2+ entry mechanism. J Biol Chem.2000;275: 16242-16250.","DOI":"10.1074\/jbc.M002077200"},{"key":"2020021223455579200_REF10","doi-asserted-by":"crossref","unstructured":"Song X, Lin HP, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst.2002;94: 585-591.","DOI":"10.1093\/jnci\/94.8.585"},{"key":"2020021223455579200_REF11","doi-asserted-by":"crossref","unstructured":"Kulp SK, Yang YT, Hung CC, et al. 3-phosphoinositide-dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res.2004;64: 1444-1451.","DOI":"10.1158\/0008-5472.CAN-03-2396"},{"key":"2020021223455579200_REF12","doi-asserted-by":"crossref","unstructured":"Johnson AJ, Song X, Hsu A-L, Chen C-S. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul.2001;41: 221-235.","DOI":"10.1016\/S0065-2571(00)00015-7"},{"key":"2020021223455579200_REF13","doi-asserted-by":"crossref","unstructured":"Zhu J, Huang JW, Tseng PH, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res.2004;64: 4309-4318.","DOI":"10.1158\/0008-5472.CAN-03-4063"},{"key":"2020021223455579200_REF14","doi-asserted-by":"crossref","unstructured":"Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol.2002;29: 10-24.","DOI":"10.1053\/sonc.2002.30155"},{"key":"2020021223455579200_REF15","doi-asserted-by":"crossref","unstructured":"Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol.1999;17: 2941-2953.","DOI":"10.1200\/JCO.1999.17.9.2941"},{"key":"2020021223455579200_REF16","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87: 4990-4997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"2020021223455579200_REF17","doi-asserted-by":"crossref","unstructured":"Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92: 3804-3816.","DOI":"10.1182\/blood.V92.10.3804"},{"key":"2020021223455579200_REF18","doi-asserted-by":"crossref","unstructured":"Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81: 151-157.","DOI":"10.1182\/blood.V81.1.151.151"},{"key":"2020021223455579200_REF19","doi-asserted-by":"crossref","unstructured":"Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 1999;94: 1401-1408.","DOI":"10.1182\/blood.V94.4.1401"},{"key":"2020021223455579200_REF20","doi-asserted-by":"crossref","unstructured":"Johnson LV, Walsh ML, Chen LB. Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A.1980;77: 990-994.","DOI":"10.1073\/pnas.77.2.990"},{"key":"2020021223455579200_REF21","doi-asserted-by":"crossref","unstructured":"Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem.2003;278: 12579-12589.","DOI":"10.1074\/jbc.M213093200"},{"key":"2020021223455579200_REF22","doi-asserted-by":"crossref","unstructured":"Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol.2003;21: 1466-1471.","DOI":"10.1200\/JCO.2003.06.012"},{"key":"2020021223455579200_REF23","doi-asserted-by":"crossref","unstructured":"Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91: 3379-3389.","DOI":"10.1182\/blood.V91.9.3379"},{"key":"2020021223455579200_","doi-asserted-by":"crossref","unstructured":"Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993;82: 1820-1828.","DOI":"10.1182\/blood.V82.6.1820.1820"},{"key":"2020021223455579200_REF25","unstructured":"Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10: 456-459."},{"key":"2020021223455579200_REF26","doi-asserted-by":"crossref","unstructured":"Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem.2000;275: 11397-11403.","DOI":"10.1074\/jbc.275.15.11397"},{"key":"2020021223455579200_REF27","doi-asserted-by":"crossref","unstructured":"Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J.2003;17: 1547-1549.","DOI":"10.1096\/fj.02-0947fje"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/6\/2504\/1707405\/zh800605002504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/6\/2504\/1707405\/zh800605002504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T06:54:52Z","timestamp":1585896892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/6\/2504\/20127\/A-novel-celecoxib-derivative-OSU03012-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,15]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-05-1957","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,15]]}}}